Please wait while we open this resource.
K
Clinical reviews
CLINICAL TRIALS AND NEW THERAPIES IN SJÖGREN’S DISEASE
Vishal Patel, Antonio Salas, Thomas Grader-Beck
PDF13 pages1.2 MB
Despite significant advances in understanding Sjögren’s disease (SjD), there are currently no approved disease-modifying therapies. Management remains largely symptomatic, with off-label immunomodulators used for systemic features. The document discusses recent phase 2 and phase 3 trials that have shown promising efficacy signals, indicating a shift in the therapeutic landscape. It emphasizes the importance of trial design refinements and the need for targeted treatments to address the substantial unmet needs of patients.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial
Same clinical topic · Rheumatology
EARLY TRAUMA AS THE ORIGIN OF CHRONIC INFLAMMATION: A PSYCHONEUROIMMUNOLOGICAL PERSPECTIVE
Same clinical topic · Rheumatology
IDIOPATHIC INFLAMMATORY MYOPATHIES
Same clinical topic · Rheumatology
MULTIFACTORIAL PATHOGENESIS OF RHEUMATOID ARTHRITIS
Same clinical topic · Rheumatology
SYSTEMIC LUPUS ERYTHEMATOSUS IN CRITICAL CARE: A SYSTEMATIC REVIEW OF ICU OUTCOMES AND MANAGEMENT
Same clinical topic · Rheumatology
RHEUMATOID ARTHRITIS — COMMON ORIGINS, DIVERGENT MECHANISMS
Same clinical topic · Rheumatology
RHEUMATOID ARTHRITIS IN ADULTS
Same clinical topic · Rheumatology
BIOLOGICAL THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Same clinical topic · Rheumatology
SYSTEMIC LUPUS ERYTHEMATOSUS: DIAGNOSIS AND TREATMENT
Same clinical topic · Rheumatology